Vendor comparison · 2026
CJC-1295 vendors: 23 compared on COAs and price
OtherAlso known as Modified GRF (1-29), CJC-1295 without DAC
Evidence tier
Multiple human trials
2 human trials
- Vendors carrying it
- 23
- 21 with a listed price
- Vendors with checkable COAs
- 10
- 10 publish any certificate
- Lots tested
- 15
- 15 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 3 Sept 2026
- oldest 12 Aug 2025
- Laboratories named
- 8
- most often Freedom Diagnostics Testing
- Median label gap
- 3.4%
- 67% of lots within 5% of label
- Median purity
- 99.71%
- 14 of 15 lots at 99% or above
- Lowest price per mg
- $5.50
- peer median $8.98
- Publications located
- 32
- researched since 2005
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Simple Peptide has the most checkable CJC-1295 testing in this index: 2 lots assayed by Freedom Diagnostics Testing, the newest on 25 Jun 2026. The lowest listed price is $5.50 per mg at Transition Biotech, against a peer median of $8.98. 23 vendors carrying CJC-1295 are compared below. 10 publish at least one certificate naming a checkable laboratory, 15 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying CJC-1295
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascend ScienceISO/IEC 17025 | 87.794% | $8.40 (94%) | 0 | — | — | — | — | |
| 2 | Origin LabsISO/IEC 17025 | 87.6100% | $10.00 (111%) | 0 | — | — | — | — | |
| 3 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 1 / 1 | ILS Laboratories | 99.5% | 14.2% | ||
| 4 | Simple Peptide | 83.592% | $7.00 (78%) | 2 / 2 | Freedom Diagnostics Testing | 99.8% | 14.2% | ||
| 5 | Transition Biotech | 82.391% | $5.50 (61%) | 1 / 1 | Kovera Labs | 99.7% | 3.8% | ||
| 6 | Protide HealthAge-gated COAs | 81.492% | $7.50 (84%) | 0 | — | — | — | — | no reportVisit site |
| 7 | Bench Grade Peptides | 80.789% | $9.00 (100%) | 2 / 2 | AV Analytics | 99.8% | 2.5% | ||
| 8 | Evo Labs Research | 79.387% | $5.60 (62%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Ascension Peptides | 79.189% | $10.00 (111%) | 2 / 2 | MZ Biolabs | 99.0% | 1.0% | ||
| 10 | Modern AminosISO/IEC 17025COAs need an account | 77.797% | $10.40 (116%) | 2 / 2 | Freedom Diagnostics Testing | 99.6% | 13.6% | ||
| 11 | Licensed Peptides | 76.287% | $7.80 (87%) | 1 / 1 | Vanguard Laboratory | 99.8% | 3.6% | ||
| 12 | Good Science Bio | 74.171% | $6.00 (67%) | 0 | — | — | — | — | no reportVisit site |
| 13 | NeuroLabs Research | 74.191% | $12.00 (134%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Improved Peptides | 71.787% | $6.90 (77%) | 0 | — | — | — | — | no reportVisit site |
| 15 | CuroISO/IEC 17025 | 70.997% | $15.80 (176%) | 1 / 1 | BTLabs | 99.7% | 72.0% | ||
| 16 | Northline LabsISO/IEC 17025 | 68.595% | $20.00 (223%) | 2 / 2 | ILS Laboratories | 99.4% | 3.2% | ||
| 17 | Mile High Compounds | 67.191% | $6.00 (67%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Evolve Peptides | 65.468% | $8.98 (100%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Eternal Peptides | 62.463% | $8.80 (98%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Biotech Peptides | 61.660% | $9.20 (102%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Vial Drop Labs | 59.474% | — | 1 / 1 | KMD Analytical (KMD Group LLC) | 99.7% | 0.0% | ||
| 22 | GenX Peptides | 5869% | $12.50 (139%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Extreme Peptides | 52.280% | $15.50 (173%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of CJC-1295 is on file. All 15 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
14 of 15 lots at 99% or above; median 99.71%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 1 |
| 99–99.5% | 4 |
| ≥99.5% | 10 |
67% of lots within 5% of the labelled mass; median gap 3.4%.
| Range | lots |
|---|---|
| ≤2% | 6 |
| 2–5% | 4 |
| 5–10% | 1 |
| 10–20% | 1 |
| >20% | 3 |
21 vendors, $5.50 to $20.00; median $8.98.
| Range | vendors |
|---|---|
| $5.00–$10.00 | 13 |
| $10.00–$15.00 | 5 |
| $15.00–$20.00 | 3 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 4 | 2 | 27% | Public lookup |
| ILS LaboratoriesUS | 3 | 2 | 20% | Public lookup |
| AV Analytics | 2 | 1 | 13% | No public lookup found |
| MZ BiolabsUS | 2 | 1 | 13% | No public lookup found |
| BTLabs | 1 | 1 | 7% | No public lookup found |
| KMD Analytical (KMD Group LLC)US | 1 | 1 | 7% | Public lookup |
| Kovera Labs | 1 | 1 | 7% | No public lookup found |
| Vanguard LaboratoryUS | 1 | 1 | 7% | No public lookup found |
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2005 — 21 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
32 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 15 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.30 pts purity across lots, mean label deviation 10.8%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
23 of 23 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
15 of 15 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is CJC-1295?
A synthetic analogue of growth hormone releasing hormone. Two distinct forms circulate under similar names — with and without a drug affinity complex — and vendors are not consistent about which they list. This index records the form named on the certificate rather than the form named in the product title.
Studied in published research for growth-hormone release, recovery and body composition.
Regulatory status
Labeled by vendors for laboratory research use only. Not an approved medicine.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is early-phase and preclinical. The naming ambiguity between the two forms is itself a documentation problem, and is one of the things the certificate records on this site are useful for checking.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — The Journal of clinical endocrinology and metabolism (2006)
Peer-reviewed article indexed in PubMed, published in The Journal of clinical endocrinology and metabolism (2006).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine (2026)
Peer-reviewed article indexed in PubMed, published in The American journal of sports medicine (2026).
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug testing and analysis (2019)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2019).
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Substance use & misuse (2016)
Peer-reviewed article indexed in PubMed, published in Substance use & misuse (2016).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug testing and analysis (2019)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2019).
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — American journal of physiology. Endocrinology and metabolism (2006)
Peer-reviewed article indexed in PubMed, published in American journal of physiology. Endocrinology and metabolism (2006).
Indexed studies2 human-evidence of 2
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Human — controlled trial, 2006
Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d. The study was performed at two investigational sites. Healthy subjects, ages 21-61 yr, were studied. CJC-1295 or pla…
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Human — controlled trial, 2006
Pulsatile GH secretion is considered important for many of the hormone's physiological effects. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short GHRH half-life limits its therapeutic use. A synthetic GHRH analog (CJC-1295) that binds permanently to endogenous albumin after injection (half-life = 8 d) stimulates GH and IGF-I secretion in several animal species and in normal human subjects and enhances growth in rats. Our objective was to asses…
Evidence digest
What the research on CJC-1295 actually shows
The indexed literature on CJC-1295 includes human clinical or observational records (2 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether CJC-1295 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.